Outcomes after allogeneic hematopoietic cell transplant in patients diagnosed with blast phase of myeloproliferative neoplasms: A retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation
暂无分享,去创建一个
J. Bourhis | M. Robin | I. Yakoub-Agha | D. Mclornan | A. Radujkovic | R. Schots | E. Forcade | J. Finke | M. Hunault-Berger | T. Zuckerman | K. Raj | Y. Chalandon | J. Hernández-Boluda | M. Finazzi | L. D. de Wreede | L. Gras | W. Schroyens | K. Sockel | T. Czerw | D. Avenoso | A. Bloor | N. Polverelli | N. Kröger | G. Ortí | N. Zinger | Joana Drozd-Sokolowska | J. Hernández‐Boluda
[1] Y. Natkunam,et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms , 2022, Leukemia.
[2] M. Tormo,et al. Acute leukemia arising from myeloproliferative or myelodysplastic/myeloproliferative neoplasms: A series of 372 patients from the PETHEMA AML registry. , 2022, Leukemia research.
[3] M. Heuser,et al. Reduced intensity hematopoietic stem cell transplantation for accelerated-phase myelofibrosis , 2022, Blood Advances.
[4] P. Mazza,et al. GITMO REGISTRY STUDY ON ALLOGENEIC TRANSPLANTATION IN PATIENTS AGED OVER 60 FROM 2000 TO 2017. IMPROVEMENTS AND CRITICISMS , 2021, Transplantation and Cellular Therapy.
[5] M. Robin,et al. Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party , 2021, Leukemia.
[6] P. Guglielmelli,et al. Venetoclax with azacitidine or decitabine in blast‐phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases , 2021, American journal of hematology.
[7] R. Chakraverty,et al. Graft Versus Leukemia: Current Status and Future Perspectives. , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] S. Montoto,et al. How much has allogeneic stem cell transplant-related mortality improved since the 1980s? A retrospective analysis from the EBMT. , 2020, Blood advances.
[9] H. Deeg,et al. Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABL-negative MPN in blast phase. , 2020, Blood advances.
[10] V. Najfeld,et al. Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase. , 2020, Blood advances.
[11] Y. Liu,et al. Comparison of outcomes of HCT in blast phase of BCR-ABL1- MPN with de novo AML and with AML following MDS. , 2020, Blood advances.
[12] R. Levine,et al. Leukemia secondary to myeloproliferative neoplasms , 2020 .
[13] S. Koschmieder,et al. Role of inflammation in the biology of myeloproliferative neoplasms. , 2020, Blood reviews.
[14] E. Clappier,et al. Should transplantation still be considered for Ph1-negative myeloproliferative neoplasms in transformation? , 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[15] N. Kröger,et al. Impact of primary disease on outcome after allogeneic stem cell transplantation for transformed secondary acute leukaemia , 2019, British journal of haematology.
[16] O. Odenike. How I treat the blast phase of Philadelphia chromosome-negative myeloproliferative neoplasms. , 2018, Blood.
[17] M. Minden,et al. The mutational landscape of accelerated- and blast-phase myeloproliferative neoplasms impacts patient outcomes. , 2018, Blood advances.
[18] A. Tefferi,et al. Validation of the WHO-defined 20% circulating blasts threshold for diagnosis of leukemic transformation in primary myelofibrosis , 2018, Blood Cancer Journal.
[19] P. Guglielmelli,et al. Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts , 2018, Leukemia.
[20] T. Barbui,et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion , 2018, Blood Cancer Journal.
[21] W. Vainchenker,et al. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. , 2017, Blood.
[22] Alan M. Miller,et al. Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] D. Porter,et al. International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[24] M. Nørgaard,et al. Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] Daniel Wolff,et al. Measuring Therapeutic Response in Chronic Graft-versus-host-disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus- Host Disease: Iv. Response Criteria Working Group Report , 2022 .
[26] James R Carpenter,et al. Multiple imputation of covariates by fully conditional specification: Accommodating the substantive model , 2012, Statistical methods in medical research.
[27] M. Robin,et al. Allo-SCT for Philadelphia-negative myeloproliferative neoplasms in blast phase: a study from the Societe Française de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC) , 2014, Bone Marrow Transplantation.
[28] N. Kröger,et al. Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation: a study from the Myeloproliferative Neoplasm Subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[29] Francisco Cervantes,et al. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. , 2013, Blood.
[30] S. Solomon,et al. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] N. Komatsu. [Myeloproliferative neoplasms]. , 2013, [Rinsho ketsueki] The Japanese journal of clinical hematology.
[32] O. Abdel-Wahab,et al. Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium. , 2012, Leukemia research.
[33] C. Craddock,et al. Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia , 2011, Leukemia.
[34] M. Sorror,et al. Hematopoietic cell transplantation‐comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation , 2008, Cancer.
[35] P. Lachenbruch,et al. Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[36] J. Wagner,et al. Prospective grading of graft-versus-host disease after unrelated donor marrow transplantation: a grading algorithm versus blinded expert panel review. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[37] R Storb,et al. Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA-matching, and marrow cell dose. , 1997, Blood.